| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 32.07 | -0.01 (-0.03%) | 21.26 - 40.87 | 66.3 thousand (Below Avg) |
Market data as of 11:36AM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 31.71 |
|---|---|
| Previous Close | 32.08 |
| Day's Range | 31.26 - 32.48 |
| Market Cap | 1.3B |
| Avg Volume (10 Day) | 409.4K |
| Price/Earnings (Trailing 12 Mo.) | 8.9x |
| Earnings Per Share (Trailing 12 Mo.) | 3.61 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
Business Wire - Tuesday 05/21/2013 8:10 AM ET
Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
Business Wire - Monday 05/20/2013 7:00 AM ET
Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
Business Wire - Friday 05/17/2013 7:00 AM ET
Acorda Therapeutics to Present at the UBS Global Healthcare Conference
Business Wire - Wednesday 05/15/2013 7:00 AM ET
Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Business Wire - Thursday 05/09/2013 7:00 AM ET
Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke
Business Wire - Thursday 05/09/2013 7:00 AM ET
Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
Business Wire - Monday 05/06/2013 7:00 AM ET
Acorda Therapeutics Reports First Quarter 2013 Financial Results
Business Wire - Thursday 05/02/2013 6:00 AM ET
| ACOR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 1.40% | |
| Net Income Growth (1yr) | 273.12% | |
| Total Debt/Equity | 0.01 | |
| LT Debt/Equity | 0.01 | |
| Earnings Yield | 11.24% | |
| Price/Sales | 4.25 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.39 | -2.12% |
| VIVUS Inc | 14.23 | +5.22% |
| NPS Pharmaceuticals Inc | 15.06 | +0.74% |
| Immunogen Inc | 17.23 | +1.17% |
| Sarepta Therapeutics Inc | 37.21 | +2.45% |
Data is delayed by at least 15 min.